PMID- 35235951 OWN - NLM STAT- MEDLINE DCOM- 20220506 LR - 20220716 IS - 2473-9537 (Electronic) IS - 2473-9529 (Print) IS - 2473-9529 (Linking) VI - 6 IP - 9 DP - 2022 May 10 TI - Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. PG - 2763-2772 LID - 10.1182/bloodadvances.2022007052 [doi] AB - Multiple myeloma (MM) is a plasma cell malignancy that is characterized by diverse clinical presentations. Although biochemical assessment of disease activity is commonly used to monitor treatment response, findings on magnetic resonance imaging and positron emission tomography (PET)/computed tomography (CT), among other imaging modalities, have proven to harbor prognostic value. We sought to corroborate these findings by examining the prognostic significance of fluorodeoxyglucose PET/CT scanning in the setting of newly diagnosed MM. We retrospectively analyzed 195 patients with a PET/CT available at diagnosis and at 6 months posttreatment to examine their value as an adjuvant metric to conventional hematologic responses in terms of time to next treatment (TTNT) and overall survival (OS). The median TTNT and OS for the entire cohort were 24.6 months (95% confidence interval [CI], 20.4-29.1) and 79 months (95% CI, 63.1-119.1), respectively. When comparing PET/CT negative (-) with PET/CT positive (+) patients, we found significantly prolonged median TTNT (55.2 vs 17.8 months, P < .0001) and OS (unreached vs 60.8 months, P < .0001) in the former group. We then examined the additive value of PET/CT on the hematologic response achieved at 6 months and found that PET/CT (-) is associated with significantly increased median TTNT and OS for the very good partial response (VGPR) group and the less than VGPR group. Importantly, PET/CT retained prognostic significance after adjusting for multiple other predictive variables. We conclude that a PET/CT (-) at 6 months confers a significant prognostic advantage for patients with newly diagnosed MM and adds significant value to the hematologic response assessment. CI - (c) 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. FAU - Charalampous, Charalampos AU - Charalampous C AD - Division of Hematology, Department of Internal Medicine. FAU - Goel, Utkarsh AU - Goel U AUID- ORCID: 0000-0003-1663-0325 AD - Division of Hematology, Department of Internal Medicine. FAU - Broski, Stephen M AU - Broski SM AUID- ORCID: 0000-0001-5391-9537 AD - Department of Radiology, and. FAU - Dingli, David AU - Dingli D AD - Division of Hematology, Department of Internal Medicine. FAU - Kapoor, Prashant AU - Kapoor P AD - Division of Hematology, Department of Internal Medicine. FAU - Gertz, Morie A AU - Gertz MA AUID- ORCID: 0000-0002-3853-5196 AD - Division of Hematology, Department of Internal Medicine. FAU - Lacy, Martha Q AU - Lacy MQ AUID- ORCID: 0000-0003-1193-1559 AD - Division of Hematology, Department of Internal Medicine. FAU - Dispenzieri, Angela AU - Dispenzieri A AUID- ORCID: 0000-0001-8780-9512 AD - Division of Hematology, Department of Internal Medicine. FAU - Hayman, Suzanne R AU - Hayman SR AD - Division of Hematology, Department of Internal Medicine. FAU - Buadi, Francis AU - Buadi F AUID- ORCID: 0000-0003-3214-0203 AD - Division of Hematology, Department of Internal Medicine. FAU - Hwa, Lisa AU - Hwa L AD - Division of Hematology, Department of Internal Medicine. FAU - Leung, Nelson AU - Leung N AUID- ORCID: 0000-0002-5651-1411 AD - Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN. FAU - Lin, Yi AU - Lin Y AD - Division of Hematology, Department of Internal Medicine. FAU - Gonsalves, Wilson I AU - Gonsalves WI AD - Division of Hematology, Department of Internal Medicine. FAU - Kourelis, Taxiarchis V AU - Kourelis TV AUID- ORCID: 0000-0001-8573-9434 AD - Division of Hematology, Department of Internal Medicine. FAU - Warsame, Rahma AU - Warsame R AUID- ORCID: 0000-0003-0240-0326 AD - Division of Hematology, Department of Internal Medicine. FAU - Fonder, Amie AU - Fonder A AUID- ORCID: 0000-0001-9488-8212 AD - Division of Hematology, Department of Internal Medicine. FAU - Hobbs, Miriam AU - Hobbs M AD - Division of Hematology, Department of Internal Medicine. FAU - Binder, Moritz AU - Binder M AUID- ORCID: 0000-0001-9014-9658 AD - Division of Hematology, Department of Internal Medicine. FAU - Kyle, Robert A AU - Kyle RA AD - Division of Hematology, Department of Internal Medicine. FAU - Rajkumar, S Vincent AU - Rajkumar SV AD - Division of Hematology, Department of Internal Medicine. FAU - Kumar, Shaji K AU - Kumar SK AUID- ORCID: 0000-0001-5392-9284 AD - Division of Hematology, Department of Internal Medicine. LA - eng GR - P50 CA186781/CA/NCI NIH HHS/United States PT - Journal Article PL - United States TA - Blood Adv JT - Blood advances JID - 101698425 RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Fluorodeoxyglucose F18 MH - Humans MH - *Multiple Myeloma/diagnostic imaging/therapy MH - *Positron Emission Tomography Computed Tomography/methods MH - Radiopharmaceuticals MH - Retrospective Studies PMC - PMC9092399 EDAT- 2022/03/03 06:00 MHDA- 2022/05/07 06:00 PMCR- 2022/04/29 CRDT- 2022/03/02 20:07 PHST- 2022/01/13 00:00 [received] PHST- 2022/02/20 00:00 [accepted] PHST- 2022/03/03 06:00 [pubmed] PHST- 2022/05/07 06:00 [medline] PHST- 2022/03/02 20:07 [entrez] PHST- 2022/04/29 00:00 [pmc-release] AID - 484230 [pii] AID - 2022/ADV2022007052 [pii] AID - 10.1182/bloodadvances.2022007052 [doi] PST - ppublish SO - Blood Adv. 2022 May 10;6(9):2763-2772. doi: 10.1182/bloodadvances.2022007052.